Shareholding for the Period Ended June 30, 2017
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click here12-07-2017
Shareholding for the Period Ended June 30, 2017
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2017. For more details, kindly Click herePress Release
Zydus receives final approval from the USFDA for Memantine Hydrochloride tablets.Cadila Healthcare in a long-term uptrend
Investors with a long-term perspective can buy the stock in declinesZydus starts drug trial for anaemia
Cadila Healthcare Ltd (Zydus Cadila), on Wednesday, announced commencement of a Phase-II trial investigating Zyani1, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a...Press Release
Phibro Animal Health Corporation and Zydus Cadila announce their intention to license Phibro's Poultry Vaccine TechnologiesPress Release
Zydus starts phase II trial of ZYAN1 for treating anemia in patients with CKD.Zydus Cadila gets USFDA nod for anti-diabetic drug
Cadila Healthcare Ltd (Zydus Cadila), on Tuesday, said it has received tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride tablets in the strengths of 50 mg/500mg and...Press Release
Zydus receives tentative approval from the USFDA for Sitagliptin and Metformin Hydrochloride TabletsZydus Cadila gets USFDA nod to market anti-obesity drug
Zydus Cadila has received approval from the US health regulator to market Phentermine Hydrochloride orally disintegrating tablets used for the treatment of obesity in the American market. The...